궤양성 대장염 치료 가이드라인 = SPECIAL REVIEW : Guidelines for the Management of Ulcerative Colitis

다국어 초록 (Multilingual Abstract)

Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decrease significantly during exacerbations of the disease. The incidence and prevalence ofUC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies are currently used for the management of UC. However, many challengingissues exist and sometimes these lead to differences in practice between clinicians. Therefore, Inflammatory BowelDiseases (IBD) Study Group of the Korean Association for the Study of Intestinal Diseases (KASID) set out theKorean guidelines for the management of UC. These guidelines are made by the adaptation using several foreignguidelines and encompass treatment of active colitis, maintenance of remission and indication for surgery in UC. The specific recommendations are presented with the quality of evidence. These are the first Korean treatmentguidelines for UC and will be revised with new evidences on treatment of UC. (Intest Res 2012;10:1-25)

참고문헌 (Reference)

1 김재학, "염증성 장질환 환자에서 Azathioprine/6-Mercaptopurine 치료의 부작용: 빈도와 경과" 대한소화기학회 51 (51): 291-297, 2008

2 정고은, "스테로이드 저항 중증 궤양성 대장염 환자에서 스테로이드와 Cyclosporin A의 병합 투여와 스테로이드 단독 연장 투여의 치료 효과 비교" 대한소화기학회 48 (48): 263-268, 2006

3 송인성, "궤양성 대장염의 발생률, 단기적 치료 반응 및 재발률의 변화 양상" 대한소화기학회 41 (41): 2003

4 최창환, "궤양성 대장염 진단 가이드라인" 대한소화기학회 53 (53): 145-160, 2009

5 박병준, "관해기 궤양성 대장염의 재발률 및 재발 관련 인자들" 대한소화기학회 52 (52): 21-26, 2008

6 Bernstein CN, "World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010" 16 : 112-124, 2010

7 Van Assche G, "Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial" 134 : 1861-1868, 2008

8 Riley SA, "Why do patients with ulcerative colitis relapse?" 31 : 179-183, 1990

9 Marteau P, "Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study" 42 : 195-199, 1998

10 Perencevich M, "Use of antibiotics in the treatment of inflammatory bowel disease" 12 : 651-664, 2006

11 Kornbluth A, "Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee" 105 : 501-523, 2010

12 Leo S, "Ulcerative colitis in remission: it is possible to predict the risk of relapse?" 44 : 217-221, 1989

13 Keane J, "Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent" 345 : 1098-1104, 2001

14 Van Assche G, "Treatment of severe steroid refractory ulcerative colitis" 14 : 5508-5511, 2008

15 Gómez-Reino JJ, "Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report" 48 : 2122-2127, 2003

16 Lees CW, "Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease" 27 : 220-227, 2008

17 Gisbert JP, "Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review" 103 : 1783-1800, 2008

18 Meyers S., "Therapy of inflammatory bowel disease. New med- ical and surgical approaches" Marcel Decker Inc 1-34, 1990

19 Adler DJ, "The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis" 85 : 717-722, 1990

20 Lobo AJ, "The role of azathioprine in the management of ulcerative colitis" 33 : 374-377, 1990

21 Kim YS, "The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study" 46 : 51-56, 2012

22 Brown SR, "The management of acute severe colitis: ACPGBI position statement" 10 (10): 8-29, 2008

23 George J, "The long-term outcome of ulcerative colitis treated with 6-mercaptopurine" 91 : 1711-1714, 1996

24 Kane SV, "The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review" 3 : 210-218, 2003

25 Fraser AG, "The efficacy of methotrexate for maintaining remission in inflammatory bowel disease" 16 : 693-697, 2002

26 Kim DU, "The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease" 56 : 1395-1402, 2009

27 Fraser AG, "The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30year review" 50 : 485-489, 2002

28 Sood A, "The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis" 37 : 270-274, 2002

29 Higgins PD, "Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares" 29 : 247-257, 2009

30 Baron JH, "Sulphasalazine and salicylazosulphadimidine in ulcerative colitis" 1 : 1094-1096, 1962

31 Toovey S, "Sulphasalazine and male infertility: reversibility and possible mechanism" 22 : 445-451, 1981

32 Chew CN, "Small bowel gas in severe ulcerative colitis" 32 : 1535-1537, 1991

33 Su C, "Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. Volume 2" Saunders 2499-2548, 2006

34 Criscuoli V, "Severe acute colitis associated with CMV: a prevalence study" 36 : 818-820, 2004

35 Actis GC, "Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis" 15 : 1307-1311, 2001

36 Sood A, "Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial" 19 : 14-16, 2000

37 Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease" 134 : 929-936, 2008

38 Creed TJ, "Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies" 25 : 111-122, 2007

39 Hanauer SB, "Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis" 24 (24): 37-40, 2006

40 Khan ZH, "Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience" 62 : 249-254, 2000

41 Turner D, "Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression" 5 : 103-110, 2007

42 Fellermann K, "Response of refractory colitis to intravenous or oral tacrolimus (FK506)" 8 : 317-324, 2002

43 Baumgart DC, "Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease" 17 : 1273-1281, 2003

44 Marshall JK, "Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis" 40 : 775-781, 1997

45 Marshall JK, "Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis" 9 : 293-300, 1995

46 Lakatos PL, "Recent trends in the epidemiology of inflammatory bowel diseases: up or down?" 12 : 6102-6108, 2006

47 Sandborn WJ, "Rational dosing of azathioprine and 6-mercaptopurine" 48 : 591-592, 2001

48 Van Assche G, "Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis" 125 : 1025-1031, 2003

49 Hawthorne AB, "Randomised controlled trial of azathioprine withdrawal in ulcerative colitis" 305 : 20-22, 1992

50 Ardizzone S, "Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis" 55 : 47-53, 2006

51 Berndtsson I, "Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis--a prospective study" 5 : 173-179, 2003

52 Radford-Smith GL, "Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease" 51 : 808-813, 2002

53 Parks AG, "Proctocolectomy without ileostomy for ulcerative colitis" 2 : 85-88, 1978

54 Kane SV, "Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis" 96 : 2929-2933, 2001

55 Cottone M, "Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis" 96 : 773-775, 2001

56 Ediger JP, "Predictors of medication adherence in inflammatory bowel disease" 102 : 1417-1426, 2007

57 Travis SP, "Predicting outcome in severe ulcerative colitis" 38 : 905-910, 1996

58 Kornbluth A, "Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee" 99 : 1371-1385, 2004

59 Casellas F, "Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis" 46 : 2343-2346, 1999

60 Hindorf U, "Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease" 55 : 1423-1431, 2006

61 Richards DM, "Patient quality of life after successful restorative proctocolectomy is normal" 3 : 223-226, 2001

62 Greenstein AJ, "Outcome of toxic dilatation in ulcerative and Crohn's colitis" 7 : 137-143, 1985

63 Baron JH, "Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone" 2 : 441-443, 1962

64 Moody GA, "Oral or rectal administration of drugs in IBD?" 11 : 999-1000, 1997

65 Cummings JR, "Oral methotrexate in ulcerative colitis" 21 : 385-389, 2005

66 Sutherland L, "Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis" (2) : CD000544-, 2006

67 Sutherland L, "Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis" (2) : CD000543-, 2006

68 Kamm MA, "Once-daily, high-concentration MMX mesalamine in active ulcerative colitis" 132 : 66-75, 2007

69 Rembacken BJ, "Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial" 354 : 635-639, 1999

70 Frieri G, "Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis" 47 : 410-414, 2000

71 Orlando A, "Minimizing infliximab toxicity in the treatment of inflammatory bowel disease" 40 (40): S236-S246, 2008

72 Kozarek RA, "Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease" 110 : 353-356, 1989

73 Siveke JT, "Methotrexate in ulcerative colitis" 17 : 479-480, 2003

74 Oren R, "Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial" 110 : 1416-1421, 1996

75 Masunaga Y, "Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease" 41 : 21-28, 2007

76 Dignass AU, "Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis" 7 : 762-769, 2009

77 Bernal I, "Medication-taking behavior in a cohort of patients with inflammatory bowel disease" 51 : 2165-2169, 2006

78 Kane S, "Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis" 114 : 39-43, 2003

79 Stein RB, "Medical therapy for inflammatory bowel disease" 28 : 297-321, 1999

80 Robert JH, "Management of severe hemorrhage in ulcerative colitis" 159 : 550-555, 1990

81 Jakobovits SL, "Management of acute severe colitis" 75-76 : 131-144, 2006

82 Ouyang Q, "Management consensus of inflammatory bowel disease for the Asia-Pacific region" 21 : 1772-1782, 2006

83 Toth A., "Male infertility due to sulphasalazine" 2 : 904-, 1979

84 Levi AJ, "Male infertility due to sulphasalazine" 2 : 276-278, 1979

85 d'Albasio G, "Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group" 93 : 799-803, 1998

86 Kruis W, "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine" 53 : 1617-1623, 2004

87 Sandborn WJ, "MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials" 26 : 205-215, 2007

88 Hanauer S, "Long-term use of zesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis" 95 : 1749-1754, 2000

89 Turunen UM, "Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study" 115 : 1072-1078, 1998

90 Fraser AG, "Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine" 16 : 1225-1232, 2002

91 Frieri G, "Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis" 37 : 92-96, 2005

92 Connell WR, "Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease" 343 : 1249-1252, 1994

93 Holtmann MH, "Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients" 51 : 1516-1524, 2006

94 Cohen RD, "Intravenous cyclosporin in ulcerative colitis: a five-year experience" 94 : 1587-1592, 1999

95 Wada Y, "Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment" 46 (46): S59-S65, 2003

96 Mantzaris GJ, "Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis" 37 : 58-62, 1994

97 d'Albasio G, "Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis" 33 : 394-397, 1990

98 Söderberg-Nauclér C, "Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines" 100 : 3154-3163, 1997

99 Truelove SC, "Intensive intravenous regimen for severe attacks of ulcerative colitis" 1 : 1067-1070, 1974

100 Kim JH, "Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease:a retrospective cohort study" 44 : e242-e248, 2010

101 Baert F, "Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease" 348 : 601-608, 2003

102 Colombel JF, "Infliximab, azathioprine, or combination therapy for Crohn's disease" 362 : 1383-1395, 2010

103 Sands BE, "Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study" 7 : 83-88, 2001

104 Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis" 353 : 2462-2476, 2005

105 Regueiro M, "Infliximab for hospitalized patients with severe ulcerative colitis" 40 : 476-481, 2006

106 Järnerot G, "Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study" 128 : 1805-1811, 2005

107 Yamamoto-Furusho JK, "Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids" 25 : 383-386, 2008

108 Shivananda S, "Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)" 39 : 690-697, 1996

109 Moskovitz DN, "Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis" 4 : 760-765, 2006

110 Rodemann JF, "Incidence of Clostridium difficile infection in inflammatory bowel disease" 5 : 339-344, 2007

111 Sands BE, "Immunosuppressive drugs in ulcerative colitis:twisting facts to suit theories?" 55 : 437-441, 2006

112 Bebb JR, "How effective are the usual treatments for ulcerative colitis?" 20 : 143-149, 2004

113 Ueno F, "Guidelines for the management treatment of ulcerative colitis in Japan" 4 : 189-239, 2010

114 Goodgame RW, "Gastrointestinal cytomegalovirus disease" 119 : 924-935, 1993

115 Chang DK, "Follow-up ulcerative colitis:short-term outcome to medical treatment and relapse rates" 26 : 907-918, 1994

116 Korelitz BI, "Fate of the rectum and distal colon after subtotal colectomy for ulcerative colitis" 10 : 198-201, 1969

117 Ananthakrishnan AN, "Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease" 57 : 205-210, 2008

118 Travis SP, "European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management" 55 (55): i16-i35, 2006

119 Travis SP, "European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management" 2 : 24-62, 2008

120 Stange EF, "European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the diagnosis and management of ulcerative colitis:definitions and diagnosis" 2 : 1-23, 2008

121 Yang SK, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study" 14 : 542-549, 2008

122 Yang SK, "Epidemiology of inflammatory bowel disease in Asia" 7 : 260-270, 2001

123 Florin TH, "Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases" 53 : 973-979, 2004

124 Khan KJ, "Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis" 106 : 630-642, 2011

125 Ford AC, "Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis" 106 : 644-659, 2011

126 Zocco MA, "Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis" 23 : 1567-1574, 2006

127 Ford AC, "Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and metaanalysis" 106 : 601-616, 2011

128 Actis GC, "Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial" 4 : 276-279, 1998

129 Cosnes J, "Effects of appendicectomy on the course of ulcerative colitis" 51 : 803-807, 2002

130 Vermeire S, "Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease" 56 : 1226-1231, 2007

131 Yokoyama H, "Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study" 13 : 1115-1120, 2007

132 Högenauer C, "Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis" 18 : 415-423, 2003

133 Lichtenstein GR, "Effect of onceor twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis" 5 : 95-102, 2007

134 Lindgren S, "Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis" 37 : 705-710, 2002

135 Lindgren SC, "Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis" 10 : 831-835, 1998

136 de Boer NK, "Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD" 4 : 686-694, 2007

137 Kruis W, "Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis" 11 : 853-858, 1997

138 Dickinson RJ, "Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis" 26 : 1380-1384, 1985

139 Schluender SJ, "Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?" 50 : 1747-1753, 2007

140 van Bodegraven AA, "Distribution of mesalazine enemas in active and quiescent ulcerative colitis" 10 : 327-332, 1996

141 Hanauer SB, "Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial" 100 : 2478-2485, 2005

142 Nguyen M, "Cytomegalovirus reactivation in ulcerative colitis patients" 2011-, 2011

143 Domènech E, "Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy" 14 : 1373-1379, 2008

144 Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy" 330 : 1841-1845, 1994

145 Shibolet O, "Cyclosporine A for induction of remission in severe ulcerative colitis" (1) : CD004277-, 2005

146 Truelove SC, "Cortisone in ulcerative colitis; final report on a therapeutic trial" 2 : 1041-1048, 1955

147 Dick AP, "Controlled trial of sulphasalazine in the treatment of ulcerative colitis" 5 : 437-442, 1964

148 McIntyre PB, "Controlled trial of bowel rest in the treatment of severe acute colitis" 27 : 481-485, 1986

149 Kirk AP, "Controlled trial of azathioprine in chronic ulcerative colitis" 284 : 1291-1292, 1982

150 Bossa F, "Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial" 102 : 601-608, 2007

151 Chinese Cooperative Group for the Study on IBD, "Consensus on the management of inflammatory bowel disease in China in 2007" 9 : 52-62, 2008

152 Paoluzi OA, "Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study" 21 : 1111-1119, 2005

153 Fockens P, "Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group" 7 : 1025-1030, 1995

154 Gionchetti P, "Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis" 41 : 93-97, 1998

155 Gionchetti P, "Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis" 11 : 1053-1057, 1997

156 Truelove SC, "Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis" 2 : 1708-1711, 1962

157 Gisbert JP, "Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis:prospective, long-term, follow-up study of 394 patients" 28 : 228-238, 2008

158 d'Albasio G, "Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study" 92 : 1143-1147, 1997

159 Marteau P, "Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study" 54 : 960-965, 2005

160 Sandborn WJ, "Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab" 137 : 1250-1260, 2009

161 Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study" 317 : 1625-1629, 1987

162 Bitton A, "Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis" 120 : 13-20, 2001

163 Lichtenstein GR, "Clinical trial:benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials" 30 : 210-226, 2009

164 Regueiro M, "Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement" 12 : 972-978, 2006

165 Choi CH, "Clinical course in ulcerative colitis: analysis of the factors affecting the clinical courses during the first year, and the changes of the clinical courses during 5 years" 38 : 169-176, 2001

166 Present DH, "Ciprofloxacin as a treatment for ulcerative colitis-not yet" 115 : 1289-1291, 1998

167 Campbell S, "Ciclosporin use in acute ulcerative colitis: a long-term experience" 17 : 79-84, 2005

168 Mulder CJ, "Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3mg/2 g) as retention enemas in active ulcerative proctitis" 8 : 549-553, 1996

169 Domènech E, "Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis" 16 : 2061-2065, 2002

170 Sood A, "Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis" 22 : 79-81, 2003

171 Steinhart AH, "Azathioprine therapy in chronic ulcerative colitis" 12 : 271-275, 1990

172 Paoluzi OA, "Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission" 16 : 1751-1759, 2002

173 Chebli LA, "Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis" 16 : 613-619, 2010

174 Fernández-Bañares F, "Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis" 91 : 2498-2499, 1996

175 Jewell DP, "Azathioprine in ulcerative colitis: final report on controlled therapeutic trial" 4 : 627-630, 1974

176 Ardizzone S, "Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis" 25 : 330-333, 1997

177 Timmer A, "Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis" (1) : CD000478-, 2007

178 Lennard-Jones JE, "Assessment of severity in colitis: a preliminary study" 16 : 579-584, 1975

179 Koutroubakis IE, "Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies" 95 : 171-176, 2000

180 Andersson RE, "Appendectomy and protection against ulcerative colitis" 344 : 808-814, 2001

181 Lennard-Jones JE, "An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis" 1 : 217-222, 1960

182 Clark M, "American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006" 133 : 312-339, 2007

183 Lichtenstein GR, "American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease" 130 : 935-939, 2006

184 Talley NJ, "American College of Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease" 106 (106): S2-S25, 2011

185 Ogata H, "A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis" 55 : 1255-1262, 2006

186 Gan SI, "A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management" 98 : 2363-2371, 2003

187 Su C, "A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis" 132 : 516-526, 2007

188 Safdi M, "A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis" 92 : 1867-1871, 1997

189 Rosenberg JL, "A controlled trial of azathioprine in the management of chronic ulcerative colitis" 69 : 96-99, 1975

190 Gilat T, "A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis" 11 : 392-395, 1989

191 Maté-Jiménez J, "6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease" 12 : 1227-1233, 2000

192 Domènech E, "6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine" 40 : 52-55, 2005

193 Present DH, "6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity" 111 : 641-649, 1989

194 D'Arienzo A, "5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial" 85 : 1079-1082, 1990

195 Biddle WL, "5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis" 94 : 1075-1079, 1988

196 Sutherland LR, "5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada" 32 (32): 64S-66S, 1987

197 Gisbert JP, "5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review" 13 : 629-638, 2007

198 Andreoli A, "5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis" 26 : 121-125, 1994